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Continuous extrapleural infusion of ropivacaine 0.2% after
cardiovascular surgery via the lateral thoracotomy approach
Abstract
OBJECTIVE: The pharmacokinetics of ropivacaine 0.2% were evaluated during a 48-hour continuous
extrapleural infusion with 2 different infusion rates in patients undergoing cardiovascular surgery. The
hypotheses that no toxic plasma concentrations of ropivacaine would be reached and that proportionality
exists among plasma concentrations and dosage used were tested. DESIGN: A prospective, randomized,
nonblinded study. SETTING: The investigation was performed as a single-center study in the Division
of Cardiovascular Anesthesia, University Hospital of Zurich, in Switzerland. PARTICIPANTS:
Seventeen consenting adults scheduled for elective cardiovascular surgery, with or without
extracorporeal bypass, via the lateral thoracotomy approach were enrolled. INTERVENTIONS: For
postoperative pain relief, patients were randomly assigned to receive continuous extrapleural infusion of
ropivacaine 0.2% at a rate of either 6 or 9 mL/h over 48 hours. MEASUREMENTS AND MAIN
RESULTS: Plasma concentrations of ropivacaine reached toxic levels (>2.2 mg/L) in 25% of cases. No
proportionality of plasma concentrations of ropivacaine existed when the 2 dosing regimens were
compared. CONCLUSIONS: Plasma concentrations of ropivacaine, administered at the given dose and
rates during continuous extrapleural infusion, are unpredictable and may reach toxic levels in patients
undergoing major cardiothoracic surgery.
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Abstract 
Objective: The pharmacokinetics of ropivacaine 0.2% were evaluated during a 
48-h continuous extrapleural infusion with two different infusion rates, in 
patients undergoing cardiovascular surgery. We tested the hypotheses that no 
toxic plasma concentrations of ropivacaine would be reached and that 
proportionality exists between plasma concentrations and dosage used. 
Design: The study had a prospective, randomized, non-blinded design.  
Setting: The investigation was performed as a single-centre study in the Division 
of Cardiovascular Anesthesia, University Hospital of Zurich. 
Participants: We enrolled 17 consenting adults scheduled for elective 
cardiovascular surgery, with or without extracorporeal bypass, with lateral 
thoracotomy approach. 
Interventions: For postoperative pain relief, patients were randomly assigned to 
receive continuous extrapleural infusion of ropivacaine 0.2% at a rate of either 6 
or 9ml/hr over 48 hours. 
Measurements and Main Results: Plasma concentrations of ropivacaine 
reached toxic levels (>2.2 mg/L) in 25% of cases. No proportionality of plasma 
concentrations of ropivacaine existed when the two dosing regimens were 
compared.  
Conclusions: Plasma concentrations of ropivacaine, administered at the given 
dose and rates during continuous extrapleural infusion, are unpredictable and 
may reach toxic levels in patients undergoing major cardiothoracic surgery. 
 
 
Introduction 
For patients selected for cardiovascular surgery, the left thoracotomy approach 
is a suitable alternative to the standard median sternotomy (1). However, pain 
after thoracic surgery has long been recognized as a cause of postoperative 
pulmonary morbidity (2), and is associated with inadequate ventilation, 
insufficient coughing, atelectasis, mucous plugging, hypoxia, and pulmonary 
infection (3,4). Parenteral opioids relieve acute postoperative pain in many 
patients at rest, but are associated with side effects such as respiratory 
depression, nausea, and bowel dysfunction.  
The health of patients undergoing cardiovascular surgery is often compromised 
by cardiac performance and pulmonal function. This limits the postoperative 
administration of opioids. Epidural analgesia has been widely advocated as a 
means of controlling postthoracotomy pain (5,6), but its use is controversial 
when extracorporeal circulation is used (7).  
The use of an extrapleural catheter, originally described by Sabanathan and 
associates (8), is a valid alternative to continuous epidural analgesia for 
relieving postthoracotomy pain (2,9,10).  In contrast to bupivacaine, only one 
study provides information about the pharmacokinetics and efficacy of 
ropivacaine during long-term continuous extrapleural infusion (11). It is thought 
to possess a greater margin of safety than bupivacaine, however (12,13). 
The aim of this study was to evaluate the pharmacokinetics of a 48-hour 
continuous extrapleural ropivacaine infusion following cardiovascular surgery 
with lateral thoracotomy. We assessed the pharmacokinetics of ropivacaine 
0.2%, applied at a rate of 6 or 9ml/h. The primary endpoints were the plasma 
concentrations of total and unbound ropivacaine, and [alpha]1-acid glycoprotein. 
Our hypotheses were that no toxic plasma concentrations of ropivacaine would 
be reached (12) and that proportionality exists between plasma concentrations 
and dosage used. 
 
Materials and Methods 
Patients  
We performed a power analysis using previously published data (14) to 
determine the sample size where blood concentrations of total and unbound 
ropivacaine at the chosen infusion rates are expected to be different:. A two 
sided t-test with an error level of 0.05 and a power of 80% resulted in a sample 
size of total 16 patients. After obtaining institutional ethics committee approval 
(University Hospital of Zurich, Switzerland) and written informed consent, adult 
patients were prospectively enrolled when scheduled for elective cardiovascular 
surgery – with or without extracorporeal circulation - in which lateral 
thoracothomy was the chosen surgical approach.  Exclusion criteria were any 
contraindications to extrapleural analgesia (such as pleural disease); known 
allergy to ropivacaine, propacetamol, and nicomorphine; administration of local 
anesthetics within 7 days prior to the present study; pregnancy and women 
without adequate contraception; concomitant medication with potent cytochrome 
P-450 1A2 inhibitors (such as fluvoxamine and ciprofloxacin); gamma-GT 
>100IU/l; creatinine >2.4mg/dl; neurologic disease and neuropsychiatric 
disorders.  
 
Surgical procedures 
Using computer-generated randomization, patients were allocated to receive a 
continuous extrapleural infusion of ropivacaine 0.2% postoperatively, at a rate of 
either 6 or 9 ml/h (12 or 18 mg/h). These infusion rates were chosen in order to 
compare the results directly with the study of Ekatodramis et al.  (14). 
Intraoperative analgesia was performed with fentanyl (Fentanyl-Janssen® 
Janssen-Cilag AG, Switzerland), max. 0.01mg/kg, given within the first two 
hours of surgery and then completed with remifentanil (Ultiva® GlaxoSmithKline 
AG, Switzerland) continuous infusion according to the patients needs. One-lung 
ventilation was introduced before thoracotomy was performed at the level of the 
4th to 5th intercostal space, without fracturing a rib. The cannulation techniques 
for the extracorporeal perfusion – if needed - varied between cases according to 
the need of the procedure (full or partial cardiopulmonal bypass, selective 
cerebral perfusion). At the end of the operation and before closing the thoracic 
wall, the surgeon created an extrapleural pocket for two to three interspaces 
above and below the thoracotomy. A multiorifice catheter (20-gauge, SIMS 
Portex Ltd. Hythe, UK) was placed with the catheter in the inferior part of one 
pocket and the tip directed to the superior part as described by Watson et al. 
(15). 10mL sodium chloride 0.9% were injected to prevent occlusion of the 
catheter. Sedated and ventilated patients were then transferred to the intensive 
care unit. Sedation and analgesia continued with propofol (Disoprivan® 2%, 
AstraZeneca AG, Switzerland) and remifentanil until patients were 
hemodynamically stable and core temperature was at least 36°C. By the time 
the patients recovered from sedation and the visual analog scale (VAS; ranging 
from 0mm = ‘no pain’ to 100mm = ‘worst pain imaginable’) was >30mm (defined 
as time t0), a bolus of 30ml ropivacaine 0.2 % (Naropin® 0.2%, AstraZeneca 
AG, Switzerland) was administered through the extrapleural catheter for an 
initial block. A continuous infusion of 6ml /h or 9ml/h ropivacaine 0.2% through 
the extrapleural catheter was administered immediately thereafter. 1g 
paracetamol (Perfalgan® 1g, UPSAMEDICA GmbH, Switzerland) was given 
every 6 hours and intravenous nicomorphine (Vilan®, SYNMEDIC AG, 
Switzerland) was scheduled for breakthrough pain. No specific study fluid 
management was pursued. Replacement was guided by basal need, blood loss, 
blood pressure, coagulation and excretion. Extrapleural infusion of ropivacaine 
was maintained for 48h (t48). 
Pain was assessed by nurses or the investigator, who were not blinded to the 
infusion rate, every 20 minutes for the first hour after arriving on ICU and then 
hourly until t48. Special attention was given to clinical signs and symptoms of 
local anesthetic toxicity such as light-headedness, tinnitus and seizures, noting 
that those signs could be tempered by paracetamol or nicomorphine. 
Sample collection and analysis 
Blood was collected from a central venous line which was used only for the 
administration of Ringer’s lactate. Blood samples of 8ml were taken at the 
following timepoints: t= 1/6, 1/3, 1/2, 1, 3, 6, 18, 30, 48, 50, 52 and 54 hours. 
The samples were taken in heparinized tubes (Venoject®; Terumo, Leuven, 
Belgium), and plasma was separated by centrifugation at room temperature 
within 60min of collection. The plasma was stored at -20°C until drug assay. 
Total plasma concentrations of ropivacaine and unbound plasma 
concentrations of ropivacaine were determined. Levels of [alpha]1-acid 
glycoprotein were also measured because it has the potential advantage to 
buffer the free concentration of ropivacaine, providing a protective 
mechanism against toxic reactions. The total ropivacaine plasma 
concentration was determined by liquid chromatography with mass 
spectrometry using electrospray ionization. Unbound plasma ropivacaine 
fraction was determined by the same method following ultrafiltration of the 
sample. Concentration of [alpha]1-acid glycoprotein was measured by 
nephelometry.  
Data analysis and statistics 
The highest drug concentration after the start of the extrapleural infusion (Cmax), 
the time to reach Cmax (tmax), and the plasma concentration at the end of the 
infusion (Cend) were derived directly from the data for total and unbound 
ropivacaine. The unbound fraction (fu) of ropivacaine was calculated as 
unbound concentration (Cu) divided by total concentration in the same sample. 
Following the end of infusion, the terminal half-life (t1/2) was determined for total 
ropivacaine by linear regression of the four last data points on the plasma 
concentration-versus-time curve. Plasma clearance of total (CLtot) and unbound 
(CLu) were estimated after 6 hours and at the end of the infusion, assuming 
steady state at those time points after extrapleural administration i.e., CLtot = 
rate of infusion/Ctot. Using the linear trapezoidal rule, the area under the total 
(AUCtotal) as well as the unbound (AUCunbound) plasma concentration-time curve 
was calculated by numeric integration for the time during the continuous 
infusion (t0 – t48). 
For data analysis STATISTICA software version 6 (StatSoft©) was used. To 
analyze demographic and surgical data, amount of fentanyl intraoperatively, 
time between end of surgery and injection of the first bolus of ropivacaine at t0, 
amount of blood products during the study period (t0 – t54), postoperative 
consumption of intravenous nicomorphine and pharmacokinetic data (Cmax, tmax, 
fu, t1/2, CLtot, CLu,app, AUC) a Mann-Whitney test was used. Fisher’s exact test 
was used to compare categorical data. ANOVA corrected for repeated 
measures was applied to compare plasma concentrations of total and unbound 
ropivacaine and of [alpha]1-acid glycoprotein. The relationship between protein 
concentration, total dose per bodyweight or time and fraction of unbound 
plasma concentration was studied by fitting a multiple regression line to the 
data. Simple linear regression was used to study the relationship between 
weight, height, blood loss, substituted blood products, liver function parameters, 
fluid balance and infusion rate for both total and unbound plasma concentration. 
All results are presented as mean ± SD or median/upper quartile/lower quartile. 
A P value <0.05 was considered to be statistically significant. 
 
Results 
Patients and surgical procedures 
A total of 17 patients were enrolled in the study: 9 patients were randomized to 
receive ropivacaine 6ml/h and 8 patients to receive 9ml/h. One patient in the 
9ml/h group was excluded from the study because the extrapleural catheter was 
removed during reexploration of the thorax. Data from 9 patients in the 6ml/h 
group and 7 patients in the 9ml/h group were analyzed. 11 patients received a 
thoracic aorta graft or a mitral valve repair, 1 patient underwent aortic isthmus 
stenosis graft repair, 1 closure of atrial septal defect and 3 patients had surgery 
for other problems. 
Demographic data were statistically similar in both groups, as summarized in 
Table 1.  Also, the surgery time, time between end of surgery and injection of 
the first bolus of ropivacaine (t0), the amount of blood products needed during 
the study period, and the time of extracorporeal circulation did not differ 
between the two study groups (Table 2). However, there was an unexplained  
trend towards longer surgery time, longer time of extracorporeal circulation and 
higher need for fluid and blood product replacement in the higher dosage group.  
 
Pharmacokinetic data 
Plasma concentrations of total and unbound ropivacaine and of [alpha]1-acid 
glycoprotein increased constantly during the continuous infusion in both groups, 
without reaching a clear steady state (Figure 1).  
Table 3 shows measured and calculated pharmacokinetic data in the two 
groups. The only significant differences observed between the two groups were 
in the unbound fractions (fu30min and fuend, P <0.001). The unbound fractions 
decreased significantly over time within each group (fu30min and fuend, P <0.05). 
The total plasma clearance (CLtot) and the calculated unbound ropivacaine 
clearance (CLu) were independent of the infusion dose, but decreased 
significantly between 6 hours and the end of treatment: Cltot in the 6ml/h group 
decreased by 33% (range -6 to –46%); Cltot in the 9ml/h group decreased by 
48% (range -15 to –74%); Clu in the 6ml/h group decreased by 52% (range -20 
to –110%); Clu in the 9ml/h group decreased by 70% (range -13 to –190%) (P 
<0.05 for all values).  
In order to measure the average total and unbound ropivacaine concentrations 
during the infusion period, the area under the curve (AUC) was calculated. 
AUCtotal was equal for both groups (6ml/h: 18.9 ± 10.9mg*s*l-1; 9ml/h vs. 22.0 ± 
15.5mg*s*l-1, P=0.64). AUCunbound was significantly different between the groups 
(6ml/h: 0.35 ± 0.17mcg*s*l-1 vs. 9ml/h: 0.83 ± 0.55mcg*s*l-1, P=0.02) (Figure 2). 
A significant postoperative increase in [alpha]1-acid glycoprotein levels was 
observed between the start and end of the extrapleural infusion in both groups 
(6ml/h: 0.77 ± 0.43mg/ml vs. 1.47 ± 0.50mg/ml, P <0.05; 9ml/h: 0.79 ± 
0.42mg/ml vs. 1.60 ± 0.57mg/ml, P<0.05). However, [alpha]1-acid glycoprotein 
levels were similar in both goups.  
The terminal half-life after the end of the infusion was 4.9 ± 3.2h in the 6ml/h 
group and 6.9 ± 4.8 h in the 9ml/h group (P>0.05) (Table 3). No linear 
correlation could be established between the highest concentration of total or 
unbound plasma concentration of ropivacaine and weight, height, blood loss, 
substituted blood products, liver function parameters, infusion rate of 
ropivacaine or fluid balance. Also, plasma concentrations of ropivacaine and 
[alpha]1-acid glycoprotein did not correlate with presence of extracorporeal 
circulation. Multiple linear regression revealed that the level of [alpha]1-acid 
glycoprotein was significantly correlated with levels of unbound ropivacaine in 
plasma (r=0.95, P <0.001, n=12). Total ropivacaine plasma concentration, total 
dose per body weight and time had no correlation.  
During the investigation, no symptoms of local anasthetic toxicity or clinical 
signs of local inflammation at the catheter insertion site were observed. 
The 6ml/h group required a higher amount of nicomorphine for breakthrough 
pain (6ml/h: 1.5 ± 1.3mg/kg vs. 9ml/h: 0.4 ± 0.3 mg, P<0.01), measured 48 
hours after starting the infusion. There was a trend for higher VAS values in the 
6ml/h group (Figure 3). 
 
Discussion 
The main conclusion of this study is that, during continuous extrapleural infusion 
of ropivacaine 0.2% for postthoracotomy pain, plasma concentrations of total 
and unbound ropivacaine are unpredictable. In addition, toxic ropivacaine levels 
were reached in 25 % of patients in the study population (1 case in the low 
dosage group and 3 cases in the high dosage group). 
 
Several aspects of our results were not in accordance with previous 
investigations. In contrast with previous studies, we did not observe significant 
dose-proportional increases in plasma concentrations of total or unbound 
ropivacaine following infusion (14,16,17). Furthermore, we did not observe any 
correlations between maximum concentrations of total or unbound ropivacaine 
and factors (such as body weight, height, blood loss, substituted blood 
products, fluid balance, liver function parameters, use of extracorporeal 
circulation or dose per bodyweight) that may influence ropivacaine 
concentrations. 
 
In four patients, total ropivacaine concentrations exceeded 2.2mg/L, a level 
previously determined toxic in healthy subjects after intravenous infusion of 
ropivacaine (12). Three of those patients were in the high dosage group, 
suggesting that 9ml/h of ropivacaine 0.2% is too a high dosage for extrapleural 
analgesia. In contrast to a continuous interscalene infusion (14), the dynamics 
of drug dispersal into tissues varies more because distribution can be into 
vessel rich zones within the intercostal space or into the slowly absorbent tissue 
over the vertebral bodies (18). However, with a steady infusion rate, the 
differences in the kinetics of absorption should not influence the variability of 
plasma concentrations of the local anasthetic.  
 
In accordance with previous studies, concentrations of unbound ropivacaine - 
primarily responsible for systemic toxic effects - did not exceed 0.08 in the low 
infusion group and 0.2 in the high infusion group. Threshold levels for central 
nervous system toxicity reported by Knudsen et al. were 0.34 – 0.85 mg/l. In 
this study, the range between concentrations of unbound ropivacaine was 
considerably wider and the course over time more dispersed, especially in the 
9ml/h group. This finding is best illustrated by the difference in AUCunbound 
between the two groups, whereas AUCtotal was not different (Figure 2). 
 
Plasma levels of [alpha]1-acid glycoprotein increase as a cytokine-triggered 
response to inflammation following major surgery. The availability of [alpha]1-
acid glycoprotein as a binding partner is a key factor determining plasma 
concentrations of unbound ropivacaine. Our results confirm a strong 
relationship between [alpha]1-acid glycoprotein and unbound ropivacaine. This 
finding was consistent between groups and independent of other factors such 
as extracorporeal circulation with its possible role of disturbed hepatic perfusion. 
We therefore can assume that the increase in [alpha]1-acid glycoprotein 
enhances protein binding of unbound ropivacaine and therefore decreases the 
unbound fraction, confirming the results of earlier trials (14). However, a recent 
investigation highlighted the inter-individual variability of [alpha]1-acid 
glycoprotein and its impact on the plasma concentration of unbound ropivacaine 
(19). According to this report, the binding capacity of unbound ropivacaine was 
variable due to different individual variants of [alpha]1-acid glycoprotein. 
 The significant decrease in the estimated clearance of ropivacaine between 6 
hours and the end of the infusion suggests that a steady state was not reached 
after 48 hours. Although only an estimate of the actual value, these 
observations strongly contrast with previous studies that reported stable 
unbound concentrations during continuous infusion (11,14,20). A possible 
explanation is variability in the intrinsic metabolic clearance of ropivacaine 
(CLint), assuming that the hepatic extraction ratio of ropivacaine is low and the 
intrinsic clearance corresponds to the unbound clearance (CLu). This is 
supported by our results, in which the plasma clearance of ropivacaine also 
showed a marked and consistent decrease in the unbound fraction. We assume 
that steady state would have been reached later and therefore, a longer study 
period (>48 hours) would provide more information, although at an increased 
risk of toxicity.  
 
 It is unlikely that a single factor alone led to the unpredictable plasma 
ropivacaine concentrations observed in the current study. We propose, rather, 
that a combination of factors such as patient co-morbidities (average ASA score 
3.4), and surgeries associated with mayor fluid shifts were reflected in our 
findings. 
 
Previous studies agree on the safety of higher doses of a continuous infusion of 
ropivacaine. However, our results point out a possible, important caveat, that 
concentrations of total and unbound ropivacaine may be extremely variable in 
patients with a high ASA class undergoing cardiovascular surgery. As we have 
previously suggested, a sound evaluation of the indications and concentrations 
used for such procedures is urgently needed (21).  
The first priority is, of course, the efficacy of the method. This technique has 
been shown to be as effective as epidural analgesia for postoperative 
thoracotomy pain relief (10,15,22,23). Our results indicate a greater need for 
pain medication in the 6ml/h group than in the 9ml/h group, although we cannot 
draw conclusions from this observation because the study was not designed to 
measure the efficacy of pain relief. For this purpose, the study would require a 
greater sample size to overcome the intersubject variability seen in our trial, and 
include a control group. 
 
In summary, our study showed that in patients undergoing major cardiothoracic 
surgery, plasma concentrations of total and unbound ropivacaine are 
unpredictable during continuous extrapleural infusion. Furthermore, we 
identified a high risk of reaching toxic concentrations of ropivacaine using this 
methodology. We therefore advise a cautious use of continuous extrapleural 
infusion of ropivacaine in this population. 
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Figure  1. Plasma concentrations of total ropivacaine, unbound ropivacaine and 
[alpha]1-acid glycoprotein (AAG). Plasma concentrations were measured during a 
48-h extrapleural infusion of 6 and 9ml/h ropivacaine 0.2%, started after an initial 
bolus with 30ml ropivacaine 0.2%, and for 6 hours after stopping the infusion. Each 
line represents one patient. Mean concentrations (grey band) with 95% confidence 
intervals (dashed band) are indicated. Thick dashed line marks the total ropivacaine 
limit considered non-toxic (2.2mg/L, Knudsen et al.). Filled symbols indicate 
extracorporeal circulation during the operation, empty symbols indicate no 
extracorporeal circulation. Concentrations of unbound ropivacaine never reached 
toxic levels (0.34 – 0.85mg/l, Knudsen et al.). 
 
 
Figure  2: Area under the concentration-time curve of total and unbound ropivacaine 
during the time of the extrapleural infusion (t0 – t48). No difference between the two 
chosen infusion rates was found for total ropivacaine (* P <0.05). 
 
 
Figure  3: Average pain scores with standard deviation over the investigation period. 
0mm = no pain, 100mm = worst pain imaginable.  
 
 
 
Table 2. Surgical data    
 6 ml/h  (n=9) 9 ml/h  (n=7)  
Type of surgery (n)     
 Thoracic aorta graft 4 4  
 Mitral valve repair 1 2  
 Aorta isthmus stenosis repair 1 0  
 Closure of atrial septum defect 1 0  
 others 2 1  
Numbers of patients with extarcorporeal 
bypass during surgery (complete/partial) 
   2/2     5/1  
Time of surgery  (min)      200/155/310 295/230/390       (P = 0.17) 
Time of extracorporeal bypass 0/0/60 70/45/130 (P = 0.07) 
Time between end of surgery and t0 (min)        50/40/245      630/110/710     (P = 0.07) 
Total blood products during study period (ml/kg)   5.2/3/15.8      23/4/36         (P = 0.18) 
Total consumption of nicomorphine 
postoperatively (mg/kg) 
92/36/109 24/14/34 (P = 0.01) 
 
 
Table 2. Surgical data. Values are presented as number (n) or as median/lower 
quartile/upper quartile; P < 0.05 is considered statistically significant. 
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Fig. 1. Plasma concentrations of  total and unbound ropivacaine
and [alpha]1-acid glycoprotein
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Figure 2. Area under the total and unbound plasma concentration-time curve (AUC). 
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Fig. 3. Average pain scores
